SG65636A1 - Orally administrable pharmaceutical formulations - Google Patents

Orally administrable pharmaceutical formulations

Info

Publication number: SG65636A1
Authority: SG; Singapore
Prior art keywords: pharmaceutical formulations; orally administrable; administrable pharmaceutical; raloxifene; ethers
Prior art date: 1994-03-02

Application number

SG1997000220A

Other languages

English (en)

Inventor

Lowell Lee Gibson

Kerry John Hartauer

Julian Larry Stowers

Stephanie Ann Sweetana

Arvind Lavji Thakkar

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-02

Filing date

1997-01-30

Publication date

1999-06-22

1995-02-23 Priority to BR9500758A priority Critical patent/BR9500758A/pt

1995-02-23 Priority to ZA951497A priority patent/ZA951497B/xx

1995-02-23 Priority to IL11274695A priority patent/IL112746A/xx

1995-02-23 Priority to CA002143263A priority patent/CA2143263C/en

1995-02-24 Priority to RU95102924A priority patent/RU2118540C1/ru

1995-02-24 Priority to CZ1995499A priority patent/CZ286119B6/cs

1995-02-27 Priority to CN95100822A priority patent/CN1098684C/zh

1995-02-28 Priority to NZ270588A priority patent/NZ270588A/en

1995-02-28 Priority to DE69524981T priority patent/DE69524981T2/de

1995-02-28 Priority to PT95301291T priority patent/PT670162E/pt

1995-02-28 Priority to DK95301291T priority patent/DK0670162T3/da

1995-02-28 Priority to SI9530581T priority patent/SI0670162T1/xx

1995-02-28 Priority to EP95301291A priority patent/EP0670162B1/de

1995-02-28 Priority to AT95301291T priority patent/ATE211910T1/de

1995-02-28 Priority to ES95301291T priority patent/ES2166799T3/es

1995-03-01 Priority to FI950947A priority patent/FI117042B/fi

1995-03-01 Priority to NO19950799A priority patent/NO314286B1/no

1995-03-01 Priority to HU9500635A priority patent/HU225418B1/hu

1995-03-01 Priority to PL95307491A priority patent/PL178858B1/pl

1995-03-01 Priority to JP4177395A priority patent/JP3574210B2/ja

1995-03-01 Priority to AU13548/95A priority patent/AU684882B2/en

1997-01-30 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1997-01-30 Priority to SG1997000220A priority patent/SG65636A1/en

1997-03-26 Priority to US08/824,590 priority patent/US5811120A/en

1999-06-22 Publication of SG65636A1 publication Critical patent/SG65636A1/en

2007-05-21 Priority to GEAP200710078A priority patent/GEP20074228B/en

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
150000002148 esters Chemical class 0.000 abstract 1
150000002170 ethers Chemical class 0.000 abstract 1
239000012052 hydrophilic carrier Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 abstract 1
229960004622 raloxifene Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Hematology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

SG1997000220A 1994-03-02 1997-01-30 Orally administrable pharmaceutical formulations SG65636A1 (en)

Priority Applications (24)

Application Number	Priority Date	Filing Date	Title
BR9500758A BR9500758A (pt)	1994-03-02	1995-02-23	Formulaçoes farmacêuticas para administraçao oral
ZA951497A ZA951497B (en)	1994-03-02	1995-02-23	Orally administerable pharmaceutical formulations
IL11274695A IL112746A (en)	1994-03-02	1995-02-23	Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride
CA002143263A CA2143263C (en)	1994-03-02	1995-02-23	Orally administrable raloxifene formulations
RU95102924A RU2118540C1 (ru)	1994-03-02	1995-02-24	Фармацевтический препарат для орального применения на основе ралоксифена или его производных
CZ1995499A CZ286119B6 (cs)	1994-03-02	1995-02-24	Farmaceutický prostředek pro orální podání
CN95100822A CN1098684C (zh)	1994-03-02	1995-02-27	可口服给药的药物制剂
EP95301291A EP0670162B1 (de)	1994-03-02	1995-02-28	Pharmazeutische Zubereitungen enthaltend Raloxifen, einen oberflächenaktiven Stoff und ein wasserlösliches Verdünnungsmittel
PT95301291T PT670162E (pt)	1994-03-02	1995-02-28	Formulacoes farmaceuticas contendo raloxifeno um tensioactivo e um diluente soluvel em agua
DK95301291T DK0670162T3 (da)	1994-03-02	1995-02-28	Farmaceutiske formuleringer indeholdende raloxifen, et overfladeaktivt middel og et vandopløseligt fortyndingsmiddel
SI9530581T SI0670162T1 (en)	1994-03-02	1995-02-28	Pharmaceutical formulations containing raloxifere, a surfactant and a watersoluble diluent
NZ270588A NZ270588A (en)	1994-03-02	1995-02-28	Oral pharmaceutical formulation of raloxifene
AT95301291T ATE211910T1 (de)	1994-03-02	1995-02-28	Pharmazeutische zubereitungen enthaltend raloxifen, einen oberflächenaktiven stoff und ein wasserlösliches verdünnungsmittel
ES95301291T ES2166799T3 (es)	1994-03-02	1995-02-28	Formulaciones farmaceuticas que contienen raloxifeno, un tensioactivo y un diluyente soluble en agua.
DE69524981T DE69524981T2 (de)	1994-03-02	1995-02-28	Pharmazeutische Zubereitungen enthaltend Raloxifen, einen oberflächenaktiven Stoff und ein wasserlösliches Verdünnungsmittel
NO19950799A NO314286B1 (no)	1994-03-02	1995-03-01	Oralt administrerbart farmasöytisk preparat
HU9500635A HU225418B1 (en)	1994-03-02	1995-03-01	Orally administerable pharmaceutical formulations containing raloxifene hydrochloride and process for their preparation
PL95307491A PL178858B1 (pl)	1994-03-02	1995-03-01	Środek farmaceutyczny do podawania doustnego
JP4177395A JP3574210B2 (ja)	1994-03-02	1995-03-01	経口投与可能な医薬製剤
FI950947A FI117042B (fi)	1994-03-02	1995-03-01	Oraalisesti annettavat farmaseuttiset formulaatiot
AU13548/95A AU684882B2 (en)	1994-03-02	1995-03-01	Orally administerable pharmaceutical formulations
SG1997000220A SG65636A1 (en)	1994-03-02	1997-01-30	Orally administrable pharmaceutical formulations
US08/824,590 US5811120A (en)	1994-03-02	1997-03-26	Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
GEAP200710078A GEP20074228B (en)	1994-03-02	2007-05-21	Solid orally administerable raloxifene hydrochloride pharmaceutical formulation

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US20491594A	1994-03-02	1994-03-02
SG1997000220A SG65636A1 (en)	1994-03-02	1997-01-30	Orally administrable pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
SG65636A1 true SG65636A1 (en)	1999-06-22

Family

ID=26665140

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG1997000220A SG65636A1 (en)	1994-03-02	1997-01-30	Orally administrable pharmaceutical formulations

Country Status (22)

Country	Link
EP (1)	EP0670162B1 (de)
JP (1)	JP3574210B2 (de)
CN (1)	CN1098684C (de)
AT (1)	ATE211910T1 (de)
AU (1)	AU684882B2 (de)
BR (1)	BR9500758A (de)
CA (1)	CA2143263C (de)
CZ (1)	CZ286119B6 (de)
DE (1)	DE69524981T2 (de)
DK (1)	DK0670162T3 (de)
ES (1)	ES2166799T3 (de)
FI (1)	FI117042B (de)
HU (1)	HU225418B1 (de)
IL (1)	IL112746A (de)
NO (1)	NO314286B1 (de)
NZ (1)	NZ270588A (de)
PL (1)	PL178858B1 (de)
PT (1)	PT670162E (de)
RU (1)	RU2118540C1 (de)
SG (1)	SG65636A1 (de)
SI (1)	SI0670162T1 (de)
ZA (1)	ZA951497B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6515009B1 (en)	1991-09-27	2003-02-04	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en)	1993-01-28	1998-09-22	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en)	1993-05-13	2001-06-26	Neorx Corporation	Prevention and treatment of cardiovascular pathologies
US6491938B2 (en)	1993-05-13	2002-12-10	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
CA2223595C (en)	1995-06-07	2008-08-05	Neorx Corporation	Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
EA001257B1 (ru) *	1996-03-26	2000-12-25	Эли Лилли Энд Компани	Бензотиофены, содержащие их фармацевтические композиции и способы лечения патологических состояний с их использованием
US6458811B1 (en)	1996-03-26	2002-10-01	Eli Lilly And Company	Benzothiophenes formulations containing same and methods
ZA992858B (en)	1996-10-30	1999-07-29	Lilly Co Eli	Methods of preventing breast cancer.
CA2219377A1 (en) *	1996-10-30	1998-04-30	Eli Lilly And Company	Improvements in or relating to the prophylaxis of breast cancer
US6117911A (en)	1997-04-11	2000-09-12	Neorx Corporation	Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6413533B1 (en) *	1998-05-07	2002-07-02	The University Of Tennessee Research Corporation	Method for chemoprevention of prostate cancer
JP4798924B2 (ja) *	1999-12-13	2011-10-19	中外製薬株式会社	ヒドロキシカルボニル−ハロゲノアルキル側鎖を有する化合物
EP1241158A4 (de)	1999-12-13	2004-02-11	Chugai Pharmaceutical Co Ltd	Verbindung mit hydroxycarbonyl-halogenalkyl-seitenkette
RU2247106C2 (ru) *	1999-12-13	2005-02-27	Чугаи Сейяку Кабусики Кайся	Соединения с гидроксикарбонильными-галогеналкильными боковыми цепями
AR029538A1 (es) *	2000-07-06	2003-07-02	Wyeth Corp	Composiciones farmaceuticas de agentes estrogenicos
JP4660067B2 (ja) *	2001-04-24	2011-03-30	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	抗血管新生剤とＴＮＦαとを用いる組合せ療法
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
EP1832583A1 (de)	2002-09-30	2007-09-12	A/S GEA Farmaceutisk Fabrik	Neue Schwefelsäureadditionssalze aus Raloxifen und/oder Solvate daraus sowie pharmazeutische Zusammensetzungen damit
US20050008704A1 (en) *	2003-07-11	2005-01-13	Ray Anup Kumar	Pharmaceutical composition for solubility enhancement of hydrophobic drugs
AU2007264418B2 (en)	2006-06-30	2012-05-03	Iceutica Pty Ltd	Methods for the preparation of biologically active compounds in nanoparticulate form
WO2009049643A1 (en) *	2007-10-16	2009-04-23	Pharmathen S.A.	Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof
EP2242483B1 (de) *	2007-12-21	2013-02-20	Synthon B.V.	Raloxifen-zusammensetzung
CN102438594A (zh)	2009-04-24	2012-05-02	伊休蒂卡有限公司	吲哚美辛的新剂型
WO2011000581A2 (en) *	2009-07-02	2011-01-06	Synthon B.V.	Raloxifene composition
WO2011099942A1 (en)	2010-02-09	2011-08-18	Silverstone Pharma	New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN103006570B (zh) *	2012-10-08	2013-12-25	孙维会	一种阿佐昔芬速释微丸及其制备方法
US9561186B2 (en)	2012-11-30	2017-02-07	Pharmathen S.A.	Method for improving the bioavailability of low aqueous solubility drugs
CN103830197A (zh) *	2014-03-14	2014-06-04	崔书豪	一种盐酸雷洛昔芬分散片及其制备方法
US9526734B2 (en)	2014-06-09	2016-12-27	Iceutica Pty Ltd.	Formulation of meloxicam
WO2018062964A1 (ko) *	2016-09-30	2018-04-05	한미약품 주식회사	용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4418068A (en) *	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes
TW366342B (en) *	1992-07-28	1999-08-11	Lilly Co Eli	The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

1995
- 1995-02-23 CA CA002143263A patent/CA2143263C/en not_active Expired - Lifetime
- 1995-02-23 BR BR9500758A patent/BR9500758A/pt not_active Application Discontinuation
- 1995-02-23 IL IL11274695A patent/IL112746A/xx not_active IP Right Cessation
- 1995-02-23 ZA ZA951497A patent/ZA951497B/xx unknown
- 1995-02-24 CZ CZ1995499A patent/CZ286119B6/cs not_active IP Right Cessation
- 1995-02-24 RU RU95102924A patent/RU2118540C1/ru not_active IP Right Cessation
- 1995-02-27 CN CN95100822A patent/CN1098684C/zh not_active Expired - Lifetime
- 1995-02-28 PT PT95301291T patent/PT670162E/pt unknown
- 1995-02-28 DK DK95301291T patent/DK0670162T3/da active
- 1995-02-28 AT AT95301291T patent/ATE211910T1/de active
- 1995-02-28 EP EP95301291A patent/EP0670162B1/de not_active Expired - Lifetime
- 1995-02-28 ES ES95301291T patent/ES2166799T3/es not_active Expired - Lifetime
- 1995-02-28 NZ NZ270588A patent/NZ270588A/en unknown
- 1995-02-28 SI SI9530581T patent/SI0670162T1/xx unknown
- 1995-02-28 DE DE69524981T patent/DE69524981T2/de not_active Expired - Lifetime
- 1995-03-01 AU AU13548/95A patent/AU684882B2/en not_active Expired
- 1995-03-01 HU HU9500635A patent/HU225418B1/hu not_active IP Right Cessation
- 1995-03-01 PL PL95307491A patent/PL178858B1/pl not_active IP Right Cessation
- 1995-03-01 FI FI950947A patent/FI117042B/fi not_active IP Right Cessation
- 1995-03-01 NO NO19950799A patent/NO314286B1/no not_active IP Right Cessation
- 1995-03-01 JP JP4177395A patent/JP3574210B2/ja not_active Expired - Lifetime
1997
- 1997-01-30 SG SG1997000220A patent/SG65636A1/en unknown

Also Published As

Publication number	Publication date
PL307491A1 (en)	1995-09-04
CZ286119B6 (cs)	2000-01-12
AU684882B2 (en)	1998-01-08
IL112746A (en)	1999-12-31
FI950947A0 (fi)	1995-03-01
CA2143263A1 (en)	1995-09-03
JPH07277973A (ja)	1995-10-24
CZ49995A3 (en)	1995-10-18
NO314286B1 (no)	2003-03-03
NZ270588A (en)	1996-01-26
ZA951497B (en)	1996-08-23
HU9500635D0 (en)	1995-04-28
JP3574210B2 (ja)	2004-10-06
SI0670162T1 (en)	2002-06-30
CN1098684C (zh)	2003-01-15
NO950799L (no)	1995-09-04
CN1112420A (zh)	1995-11-29
ES2166799T3 (es)	2002-05-01
HUT72661A (en)	1996-05-28
DE69524981T2 (de)	2002-08-29
DK0670162T3 (da)	2002-03-11
BR9500758A (pt)	1995-10-24
DE69524981D1 (de)	2002-02-21
PL178858B1 (pl)	2000-06-30
FI117042B (fi)	2006-05-31
NO950799D0 (no)	1995-03-01
PT670162E (pt)	2002-06-28
EP0670162A1 (de)	1995-09-06
CA2143263C (en)	2002-01-08
FI950947L (fi)	1995-09-03
EP0670162B1 (de)	2002-01-16
AU1354895A (en)	1995-09-07
IL112746A0 (en)	1995-05-26
HU225418B1 (en)	2006-11-28
RU2118540C1 (ru)	1998-09-10
ATE211910T1 (de)	2002-02-15

Publication	Publication Date	Title
IL112746A0 (en)	1995-05-26	Orally administrable pharmaceutical formulations
ZA917528B (en)	1993-03-22	Nasal pharmaceutical composition.
GR3036937T3 (en)	2002-01-31	Pharmaceutical formulations.
GR3018318T3 (en)	1996-03-31	Pharmaceutical agents.
PH31205A (en)	1998-05-05	Pharmaceutical composition.
GR3032366T3 (en)	2000-04-27	Pharmaceutical cyclosporin composition.
EP0634459A3 (de)	1997-03-26	Formulierungen.
ZA926020B (en)	1993-03-10	Pharmaceutical combination formulation.
EP0439030A3 (en)	1991-10-16	Oral dosage forms containing pimobendan
HK58395A (en)	1995-04-28	Projected image drive game device.
CA2041417A1 (en)	1991-11-02	Treatment of pancreatic disease with 15-keto-prostaglandin compounds
OA09810A (en)	1994-04-15	Pharmaceutical composition.
EP0670166A3 (de)	1996-06-12	Oral verabreichbare Arzneimittel.
HUT71131A (en)	1995-11-28	Paramycin formulations for oral administration
ZA92110B (en)	1993-07-08	Pharmaceutical compositions.
ZA918381B (en)	1993-04-21	Pharmaceutical compositions.
AU7845098A (en)	1998-07-03	Pharmaceutical compositions comprising a 4-arylcoumarin for the treatment f vir al infections
MY117590A (en)	2004-07-31	Orally administerable pharmaceutical formulations
ZA927369B (en)	1993-06-18	Pharmaceutical compositions.
AU7757491A (en)	1991-11-27	Antineoplastic agent
ZA94434B (en)	1994-09-08	Pharmaceutical composition.
ITBZ940005V0 (it)	1994-03-11	Corpo per cassetta postale.
ZA957349B (en)	1997-03-03	Pharmaceutical formulations.
ZA92192B (en)	1993-07-12	Pharmaceutical compositions.
ZA917789B (en)	1993-03-30	Pharmaceutical preparation.